Bayer AGs expansion into new drug modalities has caught the eye, not least the launch of a dedicated cell and gene therapy unit, but the German major needs its recent launches to succeed and the late-stage pipeline to progress so that those earlier innovative projects can flourish.
That is the view of pharma R&D chief Christian Rommel who took up the post just shy of a year ago, having joined Bayer from Roche Holding AG where...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?